Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunshine Lake Pharma CoHKSE:06887 +3.00%15 PB Ratio is 4.62 as of Aug. 21, 2026, which is 11% below its 10-year median of 5.21. GuruFocus rates HKSE:06887 with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 917 Drug Manufacturers companies, Sunshine Lake Pharma Co ranks worse than 80.04% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Lake Pharma Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Lake Pharma Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sunshine Lake Pharma Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sunshine Lake Pharma Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sunshine Lake Pharma Co (HKSE:06887) has a PB Ratio of 4.62 as of Aug. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sunshine Lake Pharma Co and its competitors. This is 11% below median its historical median of 5.21. Over the past decade, Sunshine Lake Pharma Co's PB Ratio has ranged from 3.36 to 89.72. According to the industry distribution chart, Sunshine Lake Pharma Co ranks #734 out of 917 companies in the Drug Manufacturers industry, placing it in the top 80%.
Is Sunshine Lake Pharma Co's PB Ratio too high?
Sunshine Lake Pharma Co's current PB Ratio of 4.62 is 11% below median its 10-year median of 5.21. Over the past 10 years, this metric has ranged from a low of 3.36 to a high of 89.72. The Drug Manufacturers industry median PB Ratio is 1.97. Sunshine Lake Pharma Co's value of 4.62 is 134.5% above this industry median. Based on the distribution chart, Sunshine Lake Pharma Co ranks #734 out of 917 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sunshine Lake Pharma Co has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Sunshine Lake Pharma Co's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sunshine Lake Pharma Co ranks #734 out of 917 companies for PB Ratio. This places Sunshine Lake Pharma Co in the lower half of its industry. The industry median PB Ratio is 1.97. Sunshine Lake Pharma Co's value of 4.62 is 134.5% above this benchmark. Historically, Sunshine Lake Pharma Co's own PB Ratio has ranged from 3.36 to 89.72 over the past decade. While the company's 10-year median is 5.21 vs. the industry median of 1.97, Sunshine Lake Pharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.97, based on 917 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunshine Lake Pharma Co's current PB Ratio of 4.62 is 134.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sunshine Lake Pharma Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Lake Pharma Co's current PB Ratio is 4.62, which is 11% below median its own 10-year median of 5.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Lake Pharma Co stock overvalued right now?
Sunshine Lake Pharma Co (HKSE:06887) has a current PB Ratio of 4.62. The current PB Ratio is 4.62, which is 11% below median its 10-year median of 5.21 and 134.5% above the Drug Manufacturers industry median of 1.97. Sunshine Lake Pharma Co's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sunshine Lake Pharma Co (HKSE:06887), the current PB Ratio is 4.62 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sunshine Lake Pharma Co Ltd is a vertically integrated pharmaceutical company principally engaged in the research and development, manufacturing and sales of pharmaceuticals. It is focused on therapeutic areas of infectious diseases, chronic diseases and oncology. The company's revenue is mainly derived from sales of pharmaceutical products to distributors in the PRC.
15GF Score
Get the complete analysis for HKSE:06887
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06887 has been successfully added to your 
